Neoadjuvant chemotherapy (NAC) is a treatment strategy for increasing the rate of breast-conserving surgery in operable breast cancer and increasing operability in inoperable breast cancer, especially in triple-negative and human epidermal growth factor receptor 2 (HER2) overexpression subtypes. This evidence concerns the gene ERBB2 and breast cancer.